147 related articles for article (PubMed ID: 8625105)
1. Overexpression or mutation of the p53 tumor suppressor gene does not occur in malignant ovarian germ cell tumors.
Liu FS; Ho ES; Chen JT; Shih RT; Yang CH; Shih A
Cancer; 1995 Jul; 76(2):291-5. PubMed ID: 8625105
[TBL] [Abstract][Full Text] [Related]
2. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of p53 is not a feature of ovarian granulosa cell tumors.
Liu FS; Ho ES; Lai CR; Chen JT; Shih RT; Yang CH; Tsao CM
Gynecol Oncol; 1996 Apr; 61(1):50-3. PubMed ID: 8626117
[TBL] [Abstract][Full Text] [Related]
4. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor.
Lee JH; Kang YS; Park SY; Kim BG; Lee ED; Lee KH; Park KB; Kavanagh JJ; Wharton JT
Cancer Genet Cytogenet; 1995 Nov; 85(1):43-50. PubMed ID: 8536236
[TBL] [Abstract][Full Text] [Related]
5. p53 gene analysis of ovarian borderline tumors and stage I carcinomas.
Kupryjanczyk J; Bell DA; Dimeo D; Beauchamp R; Thor AD; Yandell DW
Hum Pathol; 1995 Apr; 26(4):387-92. PubMed ID: 7705816
[TBL] [Abstract][Full Text] [Related]
6. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
8. Significance of p53 expression in immature teratomas.
Charoenkwan P; Senger C; Weitzman S; Sexsmith E; Sherman CG; Malkin D; Thorner PS
Pediatr Dev Pathol; 2002; 5(5):499-507. PubMed ID: 12202994
[TBL] [Abstract][Full Text] [Related]
9. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
Liu FS; Kohler MF; Marks JR; Bast RC; Boyd J; Berchuck A
Obstet Gynecol; 1994 Jan; 83(1):118-24. PubMed ID: 8272291
[TBL] [Abstract][Full Text] [Related]
10. p53 mutations and expression in ovarian cancers: correlation with overall survival.
Wen WH; Reles A; Runnebaum IB; Sullivan-Halley J; Bernstein L; Jones LA; Felix JC; Kreienberg R; el-Naggar A; Press MF
Int J Gynecol Pathol; 1999 Jan; 18(1):29-41. PubMed ID: 9891239
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers.
Chan WY; Cheung KK; Schorge JO; Huang LW; Welch WR; Bell DA; Berkowitz RS; Mok SC
Am J Pathol; 2000 Feb; 156(2):409-17. PubMed ID: 10666369
[TBL] [Abstract][Full Text] [Related]
12. High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy.
Kihana T; Tsuda H; Teshima S; Okada S; Matsuura S; Hirohashi S
Jpn J Cancer Res; 1992 Sep; 83(9):978-84. PubMed ID: 1429209
[TBL] [Abstract][Full Text] [Related]
13. p53 gene mutations and protein accumulation in human ovarian cancer.
KupryjaĆczyk J; Thor AD; Beauchamp R; Merritt V; Edgerton SM; Bell DA; Yandell DW
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):4961-5. PubMed ID: 8506342
[TBL] [Abstract][Full Text] [Related]
14. Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis.
Kuczyk MA; Serth J; Bokemeyer C; Jonassen J; Machtens S; Werner M; Jonas U
Cancer; 1996 Nov; 78(9):1958-66. PubMed ID: 8909317
[TBL] [Abstract][Full Text] [Related]
15. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
[TBL] [Abstract][Full Text] [Related]
16. p53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervix.
Waggoner SE; Anderson SM; Luce MC; Takahashi H; Boyd J
Gynecol Oncol; 1996 Mar; 60(3):339-44. PubMed ID: 8774636
[TBL] [Abstract][Full Text] [Related]
17. Is it possible to diagnose malignancy from fluid in cystic ovarian tumors?
Yamada R; Maeda N; Oguri H; Adachi Y; Takeuchi T; Furihata M; Fukaya T
Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):96-100. PubMed ID: 24017961
[TBL] [Abstract][Full Text] [Related]
18. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
Kohler MF; Kerns BJ; Humphrey PA; Marks JR; Bast RC; Berchuck A
Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):643-50. PubMed ID: 8469448
[TBL] [Abstract][Full Text] [Related]
19. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
[TBL] [Abstract][Full Text] [Related]
20. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]